signal/raiseTrack rounds
Series AHealthtech & bio · Hangzhou

Eli Radiopharma raises nearly RMB 400m Series A led by Huagai Capital

The Hangzhou radiopharmaceutical developer, set up in 2024, will use the money to take its first drug candidates toward clinical trials.

s/rFunding deskEast Asia · 3 min read

Eli Radiopharma, a Hangzhou company developing radioactive drugs for cancer and neurological diseases, closed a Series A round of nearly RMB 400m (about $60m), it announced on 12 November 2026.

Huagai Capital led the round, with Bayland Capital, an investment firm backed by the drug research services group Pharmaron, as co-lead. Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management and Grand Flight Investment came in as new investors. The company did not disclose a valuation.

It is the fourth funding round Eli Radiopharma has announced since it was founded in 2024, and the largest by a wide margin: each of the three earlier rounds was around RMB 100m.

“The completion of this financing round marks an important milestone in Eli Radiopharma’s development and reflects our investors' confidence in our R&D strategy, technological capabilities, and long-term vision”Dr. Feng Yu, Founder and CEO, Eli Radiopharma

What Eli Radiopharma does

Radiopharmaceuticals link a molecule that seeks out a specific target in the body to a radioactive isotope. Eli Radiopharma works on so-called theranostics, using that combination both to locate disease on scans and to treat it, in oncology and in neurological conditions.

The company said it has taken several programmes aimed at new molecular targets through lead discovery and through laboratory and animal validation, and that some of them are close to an investigational new drug (IND) filing, the application needed before trials in people can begin. It did not name those programmes.

Its newsroom lists other progress. In March 2026 it said China's drug regulator, the NMPA, had cleared clinical trials of 18F-ELI-101, a PET imaging agent that targets tau protein and is meant to help diagnose Alzheimer's disease. In December 2025 it signed a joint development agreement with HTA Co. under which it can receive milestone payments as programmes reach clinical goals, plus a share of future sales. It added research agreements with Siglan Technology, a scientific computing company, in July 2026 and with United Imaging's research institute in August 2026.

Who invested

Seven existing shareholders also put in money: CSPC & Growth Bio Fund, Huaige Capital, KHK Fund, Longfeng Venture, Hongsheng Capital, Bioclub Fund and Skyfield Capital.

Huagai Capital, founded in 2012, invests in healthcare and technology and manages about RMB 35bn (about $5.2bn). Among the newcomers, InnoPinnacle Fund was set up by the Hong Kong-listed drugmaker Innovent Biologics, Grand Flight Investment is sponsored mainly by Far East Horizon, and Shenzhen Angel FOF Management was formed by Shenzhen Investment Holdings and Shenzhen Capital Group.

Cynix Wang, Huagai's chief investment officer for healthcare, pointed to two licensing deals struck in 2026 between multinational drugmakers and Chinese radiopharmaceutical developers as a sign of foreign interest in the field. Xi Zou of Bayland said radioligand therapy is likely to be used for more types of solid tumour as further treatments are approved, and that the firm expects Eli Radiopharma to compete in markets including the US and Europe.

What the money is for

Most of the money is meant to push the company's main programmes toward the clinic. It will fund preclinical studies, clinical trial applications and early clinical development, as well as the company's research platforms, hiring, and clinical and business development work.

Founder and chief executive Dr Feng Yu said the round would carry the lead programmes through preclinical work and regulatory milestones. Securities.io, which covered the round, noted that the test now is whether the company can turn its validated programmes into IND filings and early studies in patients.

The funding so far

Eli Radiopharma raised RMB 100m (about $13.7m at the time) in an angel round in December 2024, led by TaiLong VC and Yuanbio Venture Capital. In September 2025 it announced an extended angel round of more than RMB 100m, co-led by Huaige Capital, CTS Capital and KHK Fund.

In March 2026 it raised close to RMB 100m more from Longfeng Venture, Echelon Capital, Hongsheng Capital and Bioclub Fund. According to Securities.io, the company's announcement at the time put its total funding at RMB 300m. It did not give an updated total after the Series A.

Company website: eliradiopharma.com